RESEARCH DIGEST / PRECURSOR COMPARE
NMN vs NR: NAD+ Precursors in the Research Literature
Two NAD+ building blocks, two uptake routes, two evidence profiles — read side by side, with the supplement-versus-precursor distinction kept exact.
The short version
NMN vs NR is the comparison every NAD+ reader eventually reaches. Both are precursors — building blocks the body turns into NAD+ — and both are the oral answer to a basic problem: you cannot usefully swallow NAD+ itself, because it is too big to absorb intact [8]. NR (nicotinamide riboside) has the deepest controlled safety data and a clean dose-response on the NAD+ biomarker [4]. NMN (nicotinamide mononucleotide) sits one step closer to NAD+ and has the most-cited functional human result [1]. Neither has proven it changes hard clinical outcomes in people [14].
NAD+ vs NMN: why precursors are the oral route
Start with the distinction that the whole page rests on. NAD+ itself is large and charged, poorly absorbed intact, and not freely taken up by most cells [8][9]. NMN is a precursor — a smaller molecule one biochemical step from NAD+ that the body readily converts. So "NAD+ vs NMN" is not two interchangeable supplements: oral NAD+ is the poorly-absorbed parent molecule, and NMN is the studied oral building block. This is why a trial of oral NMN must never be described as "taking NAD+" — it measured a precursor, and the precursor is the point.
Distinct uptake routes
NMN and NR enter cells differently [8]. In mice, NMN is rapidly absorbed in the gut and raises NAD+ in peripheral tissues within minutes; a dedicated transporter (Slc12a8) has been described for direct NMN uptake. NR is taken up after phosphorylation by NRK kinases (NRK1/NRK2), routing through NMN on its way to NAD+, but NR is comparatively unstable in murine plasma and degrades toward nicotinamide [8]. Both intermediates raise NAD+ across multiple tissues, and both show larger responses in aged animals than young — consistent with correcting an age-related deficit [8]. The routes differ; the destination — the NAD+ pool — is shared.
Dose-response and clinical depth
On controlled human evidence, the two precursors are studied differently. NR has the cleanest dose-response on the NAD+ biomarker: 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142%, with no flushing and no significant adverse-event excess versus placebo [4]. NMN has the most-cited functional readout: 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women [1], and a multicenter 300-900 mg/day trial raised blood NAD+ at every dose and improved walking distance, naming 600 mg/day optimal [3]. In rodents, NMN 500 mg/kg/day improved glucose handling and NR 400 mg/kg/day cut diet-induced weight gain and liver fat [9]. Both reliably raise NAD+; neither has shown a hard clinical-endpoint benefit in humans [14].
Is taking NAD orally effective?
Oral NAD+ itself is poorly absorbed intact, so most researchers favor precursors [8][9]. Oral NMN and NR reliably and dose-dependently raise whole-blood NAD+ in randomized trials — NR by 22%/51%/142% at 100/300/1000 mg/day [4] — though clinical-endpoint benefits are mixed and still preliminary in humans [14]. The biomarker responds; the downstream payoff is unproven.
The regulatory wrinkle on NMN
One difference between the two precursors is regulatory, not biochemical. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was previously authorized for investigation as a drug — an unsettled marketplace dispute over NMN's supplement status, not a ban and not a safety finding [14]. NR has not faced the same challenge. This digest presents the dispute as ongoing uncertainty about how NMN may be sold, nothing more. Beyond that, supplement-grade purity varies between products and third-party testing is not guaranteed for either precursor.